NorthWest Biotherapeutics Inc (NWBO)

[MolBiol]

NW Bio Closes on First $15 Million of Financing for Substantial Expansion of European Production Capacity

Major Production Increase Being Undertaken To Meet Growing Demand

BETHESDA, Md., April 15, 2014 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of the first $15 million funding by a single institutional investor of the registered direct placement of up to $32 million which was announced by the Company last week. These first 2.27 million shares of common stock were sold for $6.60 per share.

“With the recent positive developments in our European programs, substantial additional DCVax-L production capacity will be needed,” commented Linda F. Powers, NW Bio CEO. “Today’s funding will enable us to move forward on the development of this capacity for an increasing number of patients, including early access patients outside of our clinical trials involving some initial early revenues.”